Pharmacokinetic/Pharmacodynamic Adequacy of Novel β-Lactam/β-Lactamase Inhibitors against Gram-Negative Bacterial in Critically Ill Patients

The optimal regimens of novel β-lactam/β-lactamase inhibitors (BLBLIs), ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam, are not well defined in critically ill patients. This study was conducted to identify optimal regimens of BLBLIs in these patients. A Monte Carlo simulati...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Ruiying, Sun, Dan, Li, Sihan, Chen, Jiaojiao, Teng, Mengmeng, Yang, Bo, Dong, Yalin, Wang, Taotao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389032/
https://www.ncbi.nlm.nih.gov/pubmed/34439043
http://dx.doi.org/10.3390/antibiotics10080993

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389032/
https://www.ncbi.nlm.nih.gov/pubmed/34439043
http://dx.doi.org/10.3390/antibiotics10080993

Ejemplares similares